- Home
- SLS vs SIBN Comparison
SLS vs SIBN Comparison
Compare SLS & SIBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLS | SIBN |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.7M | 576.4M |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SLS | SIBN |
|---|---|---|
| Price | $4.37 | $12.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $10.00 | ★ $24.13 |
| AVG Volume (30 Days) | ★ 6.6M | 497.2K |
| Earning Date | 03-19-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | 41.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,301,000.00 |
| Revenue This Year | N/A | $16.95 |
| Revenue Next Year | $67.40 | $14.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 21.53 |
| 52 Week Low | $0.95 | $12.50 |
| 52 Week High | $6.14 | $21.89 |
Technical Indicators
Market Signals| Indicator | SLS | SIBN |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | 30.85 |
| Support Level | $3.35 | N/A |
| Resistance Level | $5.01 | $17.05 |
| Average True Range (ATR) | 0.49 | 0.61 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 0.32 | 0.80 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.